Gene therapy for inherited muscle disease is an active area of research and
development. Initial emphasis has been on gene replacement but alternative
approaches are increasingly being considered in order to overcome difficul
ties, such as the immune rejection of transduced cells, the need for approp
riate and tissue-specific control of expression, and the requirement for sy
stemic spread in some conditions. However, the most significant obstacles t
o the clinical success of gene therapy are still the lack of efficiency and
accuracy of gene medicine delivery. Curr Opin Neurol 13:553-560. (C) 2000
Lippincott Williams & Wilkins.